The administration of TRPV4-selective and non-selective antagonists in a mouse model of colitis significantly reduced macroscopic damage, myeloperoxidase activity, and pain reduction; conversely, TRPV4 agonist treatment yielded opposite results (D’Aldebert et al., 2011). This evidence concerns the gene MPO and colitis.